trending Market Intelligence /marketintelligence/en/news-insights/trending/Lvd65O6i5LKa4eWOL4d7lQ2 content esgSubNav
In This List

Novartis to acquire Ziarco Group to boost dermatology portfolio

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Novartis to acquire Ziarco Group to boost dermatology portfolio

Novartis AG agreed to acquire Ziarco Group Ltd., a privately held company focused on developments of novel treatments in dermatology, for an undisclosed sum.

The acquisition will add a once-daily oral H4 receptor antagonist in development for eczema to Novartis' dermatology portfolio and pipeline.

The transaction is subject to customary closing conditions, including regulatory approval.